Skip to main content
Poly Medicure Ltd logo

Poly Medicure Ltd — Investor Relations & Filings

Ticker · POLYMED ISIN · INE205C01021 LEI · 335800XM9YRKFWFVXO61 BSE.NS Manufacturing
Open in API
Filings indexed 1,043 across all filing types
Latest filing 2026-05-23 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS POLYMED

About Poly Medicure Ltd

https://www.polymedicure.com

Poly Medicure Ltd, known as Polymed, is a global medical device company specializing in the design, development, and manufacture of high-quality medical consumables and equipment. The company offers a comprehensive portfolio of over 160 products across various clinical segments, including infusion therapy, oncology, anesthesia, urology, gastroenterology, blood management, and dialysis. Key offerings include IV cannulas, central venous catheters, blood collection systems, and respiratory care devices. With a strong emphasis on research and development, the company operates multiple state-of-the-art manufacturing facilities and maintains international quality certifications. Polymed serves a diverse global market, providing cost-effective and innovative healthcare solutions to hospitals and medical professionals worldwide.

Recent filings

Filing Released Lang Actions
General Updates
Share Issue/Capital Change Classification · 75% confidence The document is a formal stock exchange disclosure under SEBI LODR Regulation 30 relating to the grant of 17,500 employee stock options under the Company’s ESOP scheme. This constitutes a future share issuance/capital change event rather than, for example, a board management change, earnings release, or annual/quarterly report. It is not a repurchase but an issuance scheme announcement. Therefore the most appropriate category is Share Issue/Capital Change (SHA).
2026-05-23 English
The Disclosure is enclosed
Share Issue/Capital Change Classification · 93% confidence The document is an official stock exchange filing under SEBI LODR, notifying the grant of 17,500 employee stock options (ESOPs) by the Nomination and Remuneration Committee. It provides detailed terms of the option grant and disclosure items as per Regulation 30. This is not a full financial report, nor an earnings release, but an announcement of a capital change (issuance of new equity-linked options). It fits the definition of Share Issue/Capital Change (SHA).
2026-05-23 English
General Updates
Regulatory Filings Classification · 85% confidence The document is an intimation under SEBI Listing Regulations (Regulation 30) about the schedule of one-on-one investor/analyst meetings. It does not contain financial data, presentation materials, or voting results, nor is it a formal report publication. This is a routine compliance announcement under continuous disclosure obligations, fitting the general “Regulatory Filings” fallback category.
2026-05-21 English
enclosed
Regulatory Filings Classification · 80% confidence The document is an exchange filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), notifying the schedule of one-on-one investor meetings. It does not contain financial results, a presentation deck, nor details of fundraising or corporate actions. It is a general regulatory announcement/disclosure. Therefore, it falls under Regulatory Filings (code: RNS).
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 87% confidence The document is a formal notice under SEBI LODR regulations informing stock exchanges and investors of an upcoming earnings conference call to discuss the audited results for Q4 & full year FY2026. It contains no financial data or results itself, nor is it a transcript, earnings release, or presentation. It is a regulatory announcement (Regulation 30 disclosure) that falls into the general regulatory filings category.
2026-05-20 English
Intimation of Investors/Analysts Call for the Audited Financial Results for the quarter and year ended 31st March, 2026.
Regulatory Filings Classification · 75% confidence The document is an intimation under SEBI Regulation 30 notifying exchanges of an upcoming earnings conference call to discuss the audited Q4 and FY2026 results. It contains no actual financial data or key highlights and is not the release of the report itself, nor a transcript. This is a regulatory compliance announcement without substantive figures, so it falls under general Regulatory Filings (RNS).
2026-05-20 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.